New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar

As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.

👉 Click here to access your FREE report now!

Vincent A. Miller net worth and biography

Vincent Miller Biography and Net Worth

Director of Revolution Medicines

Vincent A. Miller, M.D. has served as a member of our board of directors since September 2017. Currently, Dr. Miller serves as Physician-in-Chief, EQRx, Inc. Previously, Dr. Miller served as Foundation Medicine’s Senior Vice President, Clinical Development from 2011 to 2013 and served as Foundation Medicine’s Chief Medical Officer from 2013 to April 2019. From 1991 to 2011, Dr. Miller served as an Attending Physician at Memorial Sloan Kettering Cancer Center. Since 2011, Dr. Miller has served as a Consulting Physician, at Memorial Sloan Kettering Cancer Center. Dr. Miller received a B.A. from the University of Pennsylvania in Mathematics and an M.D. from the University of Medicine and Dentistry of New Jersey in Newark.

What is Vincent A. Miller's net worth?: The estimated net worth of Vincent A. Miller is at least $4.00 million as of April 16th, 2018. Dr. Miller owns 70,088 shares of Revolution Medicines stock worth more than $3,999,922 as of November 21st. This net worth evaluation does not reflect any other investments that Dr. Miller may own. Learn More about Vincent A. Miller's net worth.
How do I contact Vincent A. Miller?: The corporate mailing address for Dr. Miller and other Revolution Medicines executives is 700 Saginaw Drive, Redwood City CA, 94063. Revolution Medicines can also be reached via phone at 650-481-6801 and via email at [email protected]. Learn More on Vincent A. Miller's contact information.
Has Vincent A. Miller been buying or selling shares of Revolution Medicines?: Vincent A. Miller has not been actively trading shares of Revolution Medicines during the last quarter. Learn More on Vincent A. Miller's trading history.
Who are Revolution Medicines' active insiders?: Revolution Medicines' insider roster includes Jack Anders (Insider), Jeff Cislini (General Counsel), Mark Goldsmith (Insider), Margaret Horn (COO), Stephen Kelsey (President, Research & Development), Lorence Kim (Director), Vincent Miller (Director), Sushil Patel (Director), Thilo Schroeder (Director), Peter Svennilson (Director), Xiaolin Wang (Insider), and Barbara Weber (Director). Learn More on Revolution Medicines' active insiders.
Are insiders buying or selling shares of Revolution Medicines?: In the last twelve months, insiders at the sold shares 30 times. They sold a total of 272,325 shares worth more than $11,628,071.51. The most recent insider tranaction occured on October, 14th when insider Stephen Michael Kelsey sold 16,666 shares worth more than $824,800.34. Insiders at Revolution Medicines own 8.0% of the company. Learn More about insider trades at Revolution Medicines.
Information on this page was last updated on 10/14/2024.

Vincent A. Miller Insider Trading History at Revolution Medicines

Vincent A. Miller Buying and Selling Activity at Revolution Medicines

Revolution Medicines Company Overview

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Today's Range

Now: $57.07

$56.01

$57.97

50 Day Range

MA: $49.99

$41.97

$60.60

2 Week Range

Now: $57.07

$20.51

$62.40

Volume

843,096 shs

Average Volume

1,698,615 shs

Market Capitalization

$9.60 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4